Stockreport

Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection

Acurx Pharmaceuticals, Inc.  (ACXP) 
PDF Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical TrialsAcurx is launching a ground-breaking clinical trial with [Read more]